Overview

XTX301 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

This is a first-in-human, multicenter, Phase 1, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Xilio Development, Inc.